ASCO-SITC Pre-Annual Meeting Seminar

Starts:  May 30, 2019 12:30 (CT)
Ends:  May 31, 2019 11:00 (CT)
The ASCO Pre-Annual Meeting Seminar is a multi-disciplinary seminar that will be hosted by the American Society of Clinical Oncology (ASCO) and co-sponsored by the Society for Immunotherapy of Cancer (SITC). "ImmunOcology: Effectively Integrating Immunotherapy into Today's Clinical Practice" and will be held in the afternoon on Thursday, May 30, 2019 and the morning of Friday, May 31, 2019.

Advances in cancer immunotherapy research are rapidly emerging, with an increasing rate of new approvals for the routine clinical use of immunotherapy agents in the clinic across a variety of cancers. The pace of progress in the field necessitates the continuing education of oncology clinicians to enable them to provide the most up-to-date and comprehensive immunotherapy-based treatment options to their patients. In addition, oncologists, nurses and pharmacists with basic knowledge related to utilizing immunotherapy in clinical practice continue to be challenged by issues related to patient selection and toxicity management.

This seminar is approved for physician, nursing, and pharmacist continuing education credits.


ImmunOcology: Effectively Integrating Immunotherapy into Today's Clinical Practice

Seminar Committee
Co-Chairs:

Leisha Emens, MD, PhD* – University of Pittsburgh Medical Center
Ravi Madan, MD – National Cancer Institute/National Institute of Health

Stephen Ansell, MD, PhD – Mayo Clinic
Doreen Higgins, RN, BSN, CCRP – University of Washington
Tanguy Seiwert, MD* – University of Chicago
Mario Sznol, MD* – Yale School of Medicine
Eleni Yeatras, RPh, BCOP* – US Oncology Research

*Denotes SITC Member


ImmunOncology: Effectively Integrating Immunotherapy into Today's Clinical Practice

Program Agenda
Day One: 12:30 p.m. - 5:00 p.m. Thursday, May 30, 2019

12:30 – 1:00 p.m.

Lunch

Session 1: The Biology and Biomarkers of Immunotherapy

1:00 – 1:30 p.m.

The Biology and Biomarkers of Immunotherapy
Tanguy Seiwert, MD* – University of Chicago

Session 2: Integrating Immunotherapy into Clinical Practice – Changers Over the Past Year (Part 1)

1:30 – 3:20 p.m.

Lung Cancer (Non-Small Cell)
Vamsidhar Velcheti, MD, FACP – NYU Langone, Perlmutter Cancer Center

Breast and Gynecologic Cancers
Leisha Emens, MD* – University of Pittsburgh Medical Center

Melanoma/Skin Cancers
Jose Lutzky, MD* – Mount Sinai Medical Center

Head and Neck Cancers
Priscila Goncalves, MD* – Northwell Health

3:20 – 3:35 p.m.

Break

Session 3: Integrating Immunotherapy into Clinical Practice – Changers Over the Past Year (Part 2)

3:35 – 5:00 p.m.

Gastrointestinal Malignancies
Michael Overman, MD – University of Texas MD Anderson Cancer Center

Genitourinary Malignancies
Petros Grivas, MD, PhD – University of Washington

Hematologic Malignancies
Pier Luigi Zinzani, MD, PhD – Institute of Hematology Seragnoli, University of Bologna



Day Two: 7:30 a.m. - 11:00 a.m. Friday, May 31, 2019

7:00 – 7:30 a.m.

Breakfast

Session 4: Managing Immune Toxicities: A Case-Based Discussion with Experts

7:30 – 9:00 a.m.

Neuro-Oncologist’s Perspective
David A. Reardon, MD – Dana-Farber Cancer Institute

Dermatologist’s Perspective
Jennifer Choi, MD* – Northwestern University Feinberg School of Medicine

Gastrointestinal Oncologist’s Perspective
Shilpa Grover, MD – Brigham and Women’s Hospital

Hematologic Oncologist’s Perspective
Hongtau Liu, MD, PhD – University of Chicago

Rheumatologist’s Perspective
Lenore Buckley, MD, MPHD – Yale School of Medicine

9:00 – 9:15 a.m.

Break

Session 5: Hyper-Progression: Myth or Reality?

9:15 – 10:10 a.m.

Data Supports that Hyper-Progression is Real
Aurelian Marabelle, MD, PhD – Gustave Roussy

Data Supports that Hyper-Progression is a Myth
Alexander Pearson, MD, PhD – University of Chicago

Session 6: Moving Forward – Beyond Immune Checkpoint Inhibitors

10:10 – 11:00 a.m.

Next Generation Immunotherapy: Immunocytokines and Oncolytic Viruses
Evanthia Galanis, MD – Mayo Clinic

CAR-T Cells: What’s Next?
Jeremy Abramson, MD – Massachusetts General Hospital Cancer Center, Harvard Medical School


*Denotes SITC Member

For more information, or to register, please click here.

#ClinicalTrials
#CME
#CNE
#CPE
#BladderCancer
#BreastCancers
#Colon Cancer
#GastrointestinalCancers
#GenitourinaryCancers
#GynecologicCancers
#HeadandNeckCancers
#HematologicMalignancies
#LungCancers
#Melanoma
#Non-SmallCellLungCancer
#SkinCancers
#RenalCellCarcinoma
#InPersonEvent
#Collaboration
#SITC
#AdverseEvents
#Toxicities
#Clinician
#NursePractitioner
#Oncologist
#Pharmacist
#Physician
#PhysicianAssistant
#RegisteredNurse
#2019

Location

McCormick Place
2301 S King Drive
Chicago, IL 60616